Innovations move refractive surgery along path back to the surface

Article

As the evolution in refractive surgery continues, surgeons can expect to see the journey continuing back to the surface—aided by new strategies to improve the outcomes of sub-Bowman's keratomileusis (SBK) and PRK.

As the evolution in refractive surgery continues, surgeons can expect to see the journey continuing back to the surface—aided by new strategies to improve the outcomes of sub-Bowman's keratomileusis (SBK) and PRK, said John Marshall, PhD, in his keynote address at Refractive Surgery Subspecialty Day.

SBK, involving creation of a very superficial flap using a femtosecond laser, was introduced to provide the benefits of both LASIK and PRK. Since creation of the very thin flap minimally reduces the strength of the cornea, SBK is expected to provide the biomechanical stability of PRK, but like LASIK, without the pain and haze that are sequelae of post-PRK wound healing, he said.

Looking to the future, Dr. Marshall suggested biomechanical stability after SBK can be further improved by changing the edge angle of the flap.

"Making the edge angle more oblique makes the flap stronger," said Dr. Marshall, head of the department of ophthalmology, Kings College, London.

Recognizing that wound healing is a limiting variable for PRK, Dr. Marshall suggested the surface ablation procedure will be improved by pharmacologic modulation of that process. Possible strategies include use of the simple sugar, mannose 6-phosphate, and aptamer technology.

"Studies from our group show that mannose 6-phosphate, which blocks receptor sites on keratocytes, is effective in preventing haze in animal models," Dr. Marshall said. "In addition, we have found that aptamers selectively differentiating between activated and latent keratocytes can be used for targeted wound healing control."

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
© 2025 MJH Life Sciences

All rights reserved.